3268-73-3 Usage
Uses
Used in Pharmaceutical Development:
1H-PYRAZOLO[4,3-C]PYRIDIN-3-OL is used as a therapeutic agent for the potential treatment of conditions such as obesity, addiction, and neurological disorders. Its agonistic effect on the CB1 receptor suggests it may help in managing appetite and weight, as well as in treating addiction by affecting the brain's reward system and in alleviating symptoms of certain neurological disorders by influencing pain perception and mood regulation.
Used in Research Applications:
In the scientific community, 1H-PYRAZOLO[4,3-C]PYRIDIN-3-OL serves as a valuable research tool for studying the endocannabinoid system's role in physiological and pathological processes. It aids in understanding the mechanisms of action and potential therapeutic targets within this system, contributing to the advancement of knowledge in endocannabinoid-related pharmacology.
Check Digit Verification of cas no
The CAS Registry Mumber 3268-73-3 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 3,2,6 and 8 respectively; the second part has 2 digits, 7 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 3268-73:
(6*3)+(5*2)+(4*6)+(3*8)+(2*7)+(1*3)=93
93 % 10 = 3
So 3268-73-3 is a valid CAS Registry Number.
3268-73-3Relevant academic research and scientific papers
CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES
-
Page/Page column 61, (2011/04/14)
The present invention relates to a compound of one of the formulas I to XXI; a pharmaceutical composition comprising at least one such compound; and the use of at least one such compound in preparing a drug to treat, in a subject, a genetic disease resulting from at least one splicing anomaly.
CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES
-
Page/Page column 99-100, (2009/09/04)
The present invention relates to a compound of one of the formulas I to XXI; a pharmaceutical composition comprising at least one such compound; and the use of at least one such compound in preparing a drug to treat, in a subject, a genetic disease resulting from at least one splicing anomaly.
